A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder
Trial details
- Registry ID
- NCT06775379
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as XEN1101
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive DisorderNCT06775379 | XENE | Phase 3 | Terminated | 2026-10-28Actual |
| An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE)NCT07217860 | XENE | Phase 3 | Active not recruiting | 2029-06Estimated |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)NCT07076407 | XENE | Phase 3 | Active not recruiting | 2027-05Estimated |
| An Open-Label Study of Azetukalner in Major Depressive DisorderNCT06922110 | XENE | Phase 3 | Active not recruiting | 2027-01Estimated |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)NCT07172516 | XENE | Phase 3 | Active not recruiting | 2028-06Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |